Drug Information
Drug Generic Name | RASBURICASE |
Drug Class | HYPERURICAEMIA ASSOCIATED WITH CYTOTOXIC DRUGS |
Chapter | Musculoskeletal and Joint Diseases |
is for the prophylaxis and treatment of acute hyperuricaemia, before and during initiation of chemotherapy, in patients with haematological malignancy and a high tumour burden at risk of rapid lysis. Indications: prophylaxis and treatment of acute hyperuricaemia with initial chemotherapy for haematological malignancy. Cautions: monitor closely for hypersensitivity; atopic allergies; may interfere with test for uric acid. Contra-indications: G6PD deficiency, Pregnancy: & Breast-feeding: Avoid Side Effects: fever; less commonly nausea, vomiting, diarrhoea, headache, hypersensitivity reactions (including rash, bronchospasm and anaphylaxis); haemolytic anaemia, methaemoglobinaemia. Dose: By intravenous infusion, 200 micrograms/kg once daily for up to 7 days according to plasma-uric acid concentration. |
|
Brand Name |
|